Fig. 2

Point-prevalence rates of drug-drug interactions (DDIs) over time. A: prevalence in all patients with at least one DDI and for the most frequent DDIs; B: prevalence according to pharmacokinetic and pharmacodynamic status; C: prevalence according to potential harm; D: prevalence according to the OPERAM trial randomization arm. McNemar’s test was used to assess differences in prevalence between baseline and discharge. Chi-squared test for trend was used to assess the prevalence trend between discharge and 1 year after the inclusion. Only p values ≤0.05 are specified, other p values are > 0.5 All DDIs, the types of interaction for each DDI, and details on their potential harm are described in Additional file 1. DDI 11: oral anticoagulant + an oral non-steroidal anti-inflammatory drug. DDI 12: oral anticoagulant + an antiplatelet drug. DDI 21: concomitant use of ≥2 potassium-sparing drugs. DDI 23: angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blockers + an oral non-steroidal anti-inflammatory drug. DDI 27: simvastatin + amlodipine. DDI 28: atorvastatin or simvastatin or lovastatin + amiodarone. DDI 30: calcium channel blocker + a CYP3A4 inhibitor (cytochrome P450). DDI 36: concomitant use of ≥3 centrally-acting drugs. DDI 38: selective serotonin reuptake inhibitor + another serotonergic drug. DDI 39: oral non-steroidal anti-inflammatory drug + selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor. DDI 56: oral or parenteral corticosteroid + an oral non-steroidal anti-inflammatory drug. DDI 6: digoxin + thiazide or loop diuretic. DDI 65: concomitant prescription of ≥2 drugs that reduce potassium. DDI 66: selective serotonin reuptake inhibitor + loop or thiazide diuretic. Abbreviations: M: month, PD: pharmacodynamic, PK: pharmacokinetic, M: month